ACADIA Pharmaceuticals Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Quarterly earnings show how the company performed and help investors track progress over time.
More shares issued to employees dilute existing shareholder ownership but help recruit and retain talent.
Board elections determine who oversees company decisions and protects shareholder interests.
Quarterly earnings show how the company performed and help investors track progress over time.
Leadership changes can affect drug development strategy and company direction going forward.
New board members bring skills and oversight; Poole receives $50,000 annual cash plus $200,000 equity.
Stocky reads ACADIA Pharmaceuticals Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
ACADIA Pharmaceuticals Inc.'s most recent tracked filing was a 10-Q on 5 Aug 2026: Reports second-quarter 2026 financial results.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.